1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 250 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of the report provide an orientation of cancer monoclonal dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.

A popular chapter with readers chapter 3 covers the average financial deal terms for deals signed in the cancer monoclonal antibody field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.

Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2010.

Chapter 4 covers the leading cancer monoclonal antibody deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active cancer monoclonal antibody deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma and biotech companies.

Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the Cancer monoclonal antibody partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database.

Chapter 6 brings the report to a conclusion by looking ahead to the future of cancer monoclonal antibody partnering. Newly introduced to provide readers with potential prospects and partnering insights this chapter selects emerging companies to watch in 2015 and details their recent deal making and financial activities. These companies could be potential targets for those who want to invest or partner in the coming months.

In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the cancer monoclonal antibody field preparing them with everything they need to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.

A full appendix is provided at the very end of the report which lists all the cancer monoclonal antibody deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.

Report scope

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2009
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 250 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2009

In Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 250 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law'Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of cancer monoclonal antibody deal trends since 2010
Access to headline, upfront, milestone and royalty data
Acces to the structure of cancer monoclonal antibody agreements with numerous real life case studies
Comprehensive access to over 250 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Cancer monoclonal antibody partnering by deal type
2.4. Cancer monoclonal antibody partnering by industry sector
2.5. Cancer monoclonal antibody partnering by stage of development
2.6. Cancer monoclonal antibody partnering by cancer indication
2.7. Cancer monoclonal antibody partnering by antibody type

Chapter 3 - Average financial deal terms for cancer monoclonal antibody partnering

3.1. Introduction
3.2. Disclosed financials terms for cancer monoclonal antibody partnering
3.3 Cancer monoclonal antibody partnering headline values
3.4 Cancer monoclonal antibody deal upfront payments
3.5 Cancer monoclonal antibody deal milestone payments
3.6 Cancer monoclonal antibody royalty rates

Chapter 4 - Leading cancer monoclonal antibody deals

4.1. Introduction
4.1. Most active in cancer monoclonal antibody partnering
4.2. Top cancer monoclonal antibody deals by value
4.3. Big pharma cancer monoclonal antibody dealmaking activity
4.4. Big biotech cancer monoclonal antibody dealmaking activity

Chapter 5 - Cancer monoclonal antibody contracts directory

5.1. Introduction
5.2. Cancer monoclonal antibody partnering by company A-Z
5.3. Cancer monoclonal antibody partnering stage of development
5.4. Cancer monoclonal antibody partnering by deal type
5.5. Cancer monoclonal antibody partnering by oncology therapy area
5.6. Cancer monoclonal antibody partnering by monoclonal antibody type

Chapter 6 - Future trends and companies in cancer monoclonal antibody deal making

6.1. Introduction
6.2. Future partnering trends predicted for cancer monoclonal antibody deals
6.3. Emerging companies to watch in 2015
6.4. Emerging companies dealmaking in 2010-2015
6.5. Emerging company financings in 2010-2015
6.6 Conclusion

Chapter 7 - Partnering resource centre

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions
Appendix 2 - Example monoclonal antibody cancer partnering agreement
Appendix 3 - Cancer monoclonal antibody dealmaking directory
A.3.1 Cancer monoclonal antibody deals by company A-Z
A.3.2 Cancer monoclonal antibody deals by stage of development
A.3.3 Cancer monoclonal antibody deals by deal type
A.3.4 Cancer monoclonal antibody deals by oncology therapy area
A.3.5 Cancer monoclonal antibody deals by monoclonal antibody type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Upgrades for subscription access products

Table of figures

Figure 1: Cancer monoclonal antibody partnering since 2010
Figure 2: Cancer monoclonal antibody partnering by deal type since 2010
Figure 3: Cancer monoclonal antibody partnering by industry sector since 2010
Figure 4: Cancer monoclonal antibody partnering by stage of development since 2010
Figure 5: Monoclonal antibody partnering by oncology target since 2010
Figure 6: Monoclonal antibody partnering by type since 2010
Figure 7: Cancer monoclonal antibody deals with a headline value - by stage of development
Figure 8: Cancer monoclonal antibody deals with upfront payment values - by stage of development
Figure 9: Cancer monoclonal antibody deals with milestone payment - by stage of development
Figure 10: Cancer monoclonal antibody deals with royalty rates
Figure 11: Active cancer monoclonal antibody dealmaking activity- 2010 to 2015
Figure 12: Top cancer monoclonal antibody deals by value since 2010
Figure 13: Big pharma - top 50 - cancer monoclonal antibody deals 2010 to 2015
Figure 14: Big pharma cancer monoclonal antibody deal frequency - 2010 to 2015
Figure 15: Big biotech - top 50 - cancer monoclonal antibody deals 2010 to 2015
Figure 16: Big biotech cancer monoclonal antibody deal frequency - 2010 to 2015
Figure 17: Online partnering resources
Figure 18: Forthcoming partnering events
Figure 19: Deal type definitions
Figure 20: Collaborative RandD agreement for BiTE antibodies against three undisclosed solid tumor targets

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic ...

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Monoclonal Antibody ...

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.